Why this update matters
More than a decade after the first Loeys-Dietz syndrome (LDS) management primer, MacCarrick and colleagues provide a timely update that reflects how substantially our understanding of heritable aortic disease has evolved. The central message is that LDS should not be managed as a single uniform condition. Genotype, phenotype, family history, vascular trajectory and life circumstances all contribute to risk and should shape surveillance and treatment.
From a syndrome label to genotype-informed risk
The primer highlights meaningful differences among LDS genotypes. TGFBR1- and TGFBR2-related disease generally show the greatest vascular penetrance and severity, with SMAD3 also carrying substantial risk, whereas TGFB2-, TGFB3- and SMAD2-related disease is less penetrant at the population level. This translates into genotype-informed consideration of prophylactic aortic root surgery: approximately 4.0–4.5 cm for TGFBR1, TGFBR2 and SMAD3, with higher thresholds generally considered for the less aggressive genotypes. Importantly, these values are not rigid cut-offs; rapid growth, family history of early dissection, previous vascular events, extra-aortic features, body size, sex and pregnancy plans may justify an earlier or later intervention.
The whole arterial tree matters
A second major strength is the emphasis on disease beyond the aortic root. Echocardiography remains central for longitudinal assessment of the root and ascending aorta, but cross-sectional imaging from head to pelvis is essential at baseline and should be repeated during follow-up, generally about every two years when findings are stable, with intervals tailored to genotype and vascular phenotype. This approach is supported by contemporary data showing clinically relevant aneurysms throughout the arterial tree and reinforces the need for coordinated cardiology, vascular, imaging, surgical and neurovascular expertise [1–3].
Medical therapy and life-course care
The document supports early treatment with an angiotensin-receptor blocker or beta-blocker, with consideration of dual therapy when aortic growth progresses despite monotherapy. Equally important, it moves beyond a purely diameter-driven strategy and addresses exercise, pregnancy, reproductive counselling and the multiple non-cardiovascular manifestations of LDS. Shared decision-making is therefore not an accessory to management but part of the treatment itself.
Clinical perspective
For vascular specialists, this primer is valuable because it converts an increasingly complex genotype–phenotype literature into a pragmatic framework for longitudinal care. Many recommendations necessarily remain based on observational evidence and expert consensus rather than LDS-specific randomized trials, and this uncertainty should be discussed openly with patients. Nevertheless, the direction is clear: the future of LDS management is multidisciplinary, whole-arterial-tree and increasingly personalised, rather than based on a single diagnosis or a single aortic diameter.
